H

Hospital Evangelico De Cachoeiro de Itapemirim | Centro de Pesquisas Clinicas em Oncologia

Research site

(Unclaimed)

Location

Mario Imperial, 39, 2 Andar, Ferroviarios, Cachoeiro de Itapemirim, Espirito Santo, Brazil

Site insights

Top conditions

Top treatments

Pembrolizumab

Nivolumab

5-Fluorouracil

Binimetinib

Irinotecan

MK-6482

Tislelizumab

Bemarituzumab

MEDI4736

MK-7902

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 6 total trials

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-...

Active, not recruiting

Non-small Cell Lung Cancer

NSCLC

Drug: Placebo

Drug: Tislelizumab

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenv...

Active, not recruiting

Carcinoma, Renal Cell

Drug: Belzutifan

Biological: Pembrolizumab/Quavonlimab

Locations recently updated

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102)

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Enrolling

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Other: Placebo

Drug: Nivolumab

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative t...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Domvanalimab

Drug: Nab-paclitaxel